| Literature DB >> 28087077 |
Anudeep B Pant1, Yan Wang1, Daniel W Mielcarz1, Eli J Kasper1, Kiel M Telesford1, Megan Mishra1, Azizul Haque2, Jacqueline Y Channon1, Lloyd H Kasper1, Sakhina Begum-Haque1.
Abstract
While examining the therapeutic value of anti-CD52 antibody against EAE/MS, we identified a unique subset of CD39+ Tregs in repopulating GALT tissues, a major lymphoid reservoir, which was accompanied by amelioration of disease. Furthermore, anti-CD52 treatment leads to increased expression of BDNF, IL-10, and SMAD3 in the brains of EAE mice. This condition is associated with suppression of IL-17, a critical inflammatory factor in EAE/MS progression. Additionally, we found elevated levels of CD4+CD39+ Tregs in PBMCs of RRMS patients treated with humanized anti-CD52 mAb. Thus, anti-CD52 can affect multiple immune mediated pathways involved in the pathogenesis of EAE/MS.Entities:
Keywords: Anti-CD52 mAb; CD39+ T regulatory cells; Cytokine; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Therapeutic
Mesh：
Substances：
Year: 2016 PMID： 28087077 DOI： 10.1016/j.jneuroim.2016.12.010
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478